Skip to content

Medical emergency? What to do

Merck migraine drug shows promise in clinical trial

3-RXPublished June 8, 20072 min read

Key points

  • An experimental migraine drug being developed by Merck & Co. significantly relieved pain two hours after dosing compared to a placebo in a mid-stage clinical trial, the company said on Thursday.
  • The medicine has already been advanced into late stage testing for acute treatment of migraine in adults.
  • MK-0974 is an oral calcitonin gene-related peptide (CGRP) receptor antagonist that works by blocking transmission of pain signals that lead to migraine headaches.
  • In the primary goal of measuring pain reduction from severe or moderate to mild or none two hours after dosing, MK-0974 was statistically significantly better than placebo, researchers said.

An experimental migraine drug being developed by Merck & Co. significantly relieved pain two hours after dosing compared to a placebo in a mid-stage clinical trial, the company said on Thursday.

The drug, MK-0974, also demonstrated sustained pain relief through 24 hours, according to data presented at the American Headache Society annual meeting in Chicago.

The medicine has already been advanced into late stage testing for acute treatment of migraine in adults. If it is eventually approved, it could become the first new class of migraine treatments on the market since 1991, Merck said.

The company said it remains on track to apply for U.S. approval of MK-0974 in 2009.

MK-0974 is an oral calcitonin gene-related peptide (CGRP) receptor antagonist that works by blocking transmission of pain signals that lead to migraine headaches. CGRP and its receptors are found in areas of the central and peripheral nervous system and are believed to be involved in transmission of migraine pain.

The 420-patient study tested the drug at three doses against a placebo and an older Merck migraine drug rizatriptan, which is sold under the brand name Maxalt.

In the primary goal of measuring pain reduction from severe or moderate to mild or none two hours after dosing, MK-0974 was statistically significantly better than placebo, researchers said.

The study was not large enough to accurately measure differences between the various doses of MK-0974 or between the experimental drug and rizatriptan, although the results were reported.

The proportion of patients reporting pain relief at two hours for those treated with MK-0974 was 68.1 percent at 300 milligrams; 48.2 percent at 400 mg; and 67.5 percent at 600 mg. There was a 69.5 percent response rate in the 34-patient rizatriptan group and 46.3 percent response for placebo.

MK-0974 was also significantly better than a placebo on secondary measures such as 24-hour sustained pain-relief and 24-hour sustained pain-freedom, researchers said.

The drug also appeared to relieve migraine-related symptoms, such as nausea and sensitivity to light and sound, although the study was not powered to evaluate a statistical response to those measures, researchers said.

"These results provide additional evidence of the potential benefit of CGRP receptor antagonists as a new and promising class of migraine therapies," headache specialist Dr. Alan Rapoport, one of the study's investigators, said in a statement.

Migraine headaches affect about 28 million Americans, primarily women.

The content on this site is for information only and is not a substitute for professional medical advice, diagnosis or treatment. Drug information pages are an archive and may be out of date: always follow your prescriber, your pharmacist and the current product label. In an emergency, call 911.

Keep reading

Cancer

Avastin Slows Resistant Ovarian Cancer

Progression of platinum-resistant ovarian cancer slowed by more than 50% in patients who received bevacizumab (Avastin) plus chemotherapy compared with nonplatinum chemotherapy alone, results of a randomized trial…

3 min read

Drug News

Prevnar trial results needed for CDC recommendation

Advisors to the U.S. Centers for Disease Control and Prevention on Wednesday will wait for results from a trial of Pfizer Inc's Prevnar 13 pneumonia vaccine before deciding whether to recommend its use in all adults…

1 min read

When to get help

Reading is for later. These need care now.

Call 911 or go to an emergency department if you or someone with you has any of these:

  • Chest pain or pressureEspecially with breathlessness, sweating or pain in the arm, jaw or back. It can be a heart attack.
  • Face drooping, arm weakness, slurred speechSigns of a stroke. Note the time they started: treatment works best within hours.
  • Severe trouble breathingIncluding a severe allergic reaction with swelling of the lips, tongue or throat.
  • Thoughts of suicideCall or text 988 (Suicide & Crisis Lifeline, US) any time, day or night.

Outside the US, call your local emergency number.

See a doctor within days

  1. 01A new lump, or a sore that does not healMost lumps are harmless, but anything that grows or lasts more than a few weeks should be checked.
  2. 02Unexplained weight loss or lasting fatigueLosing weight without trying, or tiredness that does not lift, can have many causes worth finding.
  3. 03A new medicine and new symptomsSide effects and interactions are common. Ask your pharmacist or prescriber before you stop anything.

General guidance only. If you are unsure how urgent a symptom is, call your doctor or a nurse advice line.